Locally Advanced Clinical Trials in Beijing, Beijing Municipality
36 recruitingBeijing, Beijing Municipality, China
Showing 1–20 of 36 trials
Recruiting
Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant Therapy for Rectal Cancer
Locally Advanced Rectal Cancer (LARC)
Beijing Friendship Hospital60 enrolled1 locationNCT07393048
Recruiting
Phase 2
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer
Pfizer320 enrolled44 locationsNCT04606446
Recruiting
Phase 1Phase 2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Metastatic Solid TumorsLocally Advanced Solid Tumors
Turning Point Therapeutics, Inc.500 enrolled165 locationsNCT03093116
Recruiting
Phase 1Phase 2
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
SarcomaCancerLeukaemia+2 more
Essen Biotech83 enrolled1 locationNCT07410676
Recruiting
Phase 1
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Locally Advanced or Metastatic Solid Tumors
ArriVent BioPharma, Inc.405 enrolled15 locationsNCT07066657
Recruiting
Phase 1Phase 2
HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors
Locally Advanced or Metastatic Pancreatic Cancer With
Shanghai Hengrui Pharmaceutical Co., Ltd.60 enrolled1 locationNCT07296341
Recruiting
Phase 1Phase 2
Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma
Unresectable Locally Advanced or Metastatic Melanoma
Shanghai JMT-Bio Inc.188 enrolled1 locationNCT07280832
Recruiting
Phase 2
Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer
Locally Advanced Colorectal Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences170 enrolled3 locationsNCT06154538
Recruiting
Phase 2
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Breast CancerNSCLCHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.200 enrolled82 locationsNCT06107686
Recruiting
Phase 3
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Locally Advanced or Metastatic Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.460 enrolled60 locationsNCT06680921
Recruiting
Phase 2
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
SafetyLocally Advanced Non-Small Cell Lung CancerThoracic Radiotherapy
JIANYANG WANG44 enrolled1 locationNCT07037680
Recruiting
Phase 3
Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy
HR+/HER2- Locally Advanced, Metastatic Breast Cancer
BeBetter Med Inc330 enrolled1 locationNCT06998108
Recruiting
Phase 2Phase 3
Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma
Locally Advanced Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital120 enrolled1 locationNCT06907602
Recruiting
Phase 2
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
Cervical CancerNeoadjuvant ChemoimmunotherapyLocally Advanced Cervical Cancer+1 more
Tongji Hospital40 enrolled12 locationsNCT06288360
Recruiting
Phase 2
Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer
Circulating Tumor DNALocally Advanced Rectal Carcinoma
Peking Union Medical College Hospital470 enrolled1 locationNCT05601505
Recruiting
Phase 2Phase 3
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
Cervical CancerConcurrent ChemoradiotherapyNeoadjuvant Chemoimmunotherapy+1 more
Tongji Hospital440 enrolled12 locationsNCT06288373
Recruiting
Phase 2
Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
HER2-positive Locally Advanced Resectable Gastric Cancer
Peking University18 enrolled1 locationNCT06023758
Recruiting
Phase 3
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
Locally Advanced Unresectable or Metastatic Gastric CancerLocally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
FutureGen Biopharmaceutical (Beijing) Co., Ltd486 enrolled1 locationNCT06177041
Recruiting
Phase 1Phase 2
A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic Non-small Cell Lung CancerLocally Advanced or Metastatic Solid Tumors
Xuanzhu Biopharmaceutical Co., Ltd.360 enrolled1 locationNCT04996121
Recruiting
Phase 2
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
Cervical CarcinomaImmunotherapyImmune Checkpoint Inhibitor+6 more
Lei Li92 enrolled1 locationNCT05311566